Literature DB >> 12029087

Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

Young-Mi Kim1, Sewook Hwang, Young-Myoeng Kim, Bo-Jeong Pyun, Tae-Yoon Kim, Seung-Taek Lee, Yong Song Gho, Young-Guen Kwon.   

Abstract

Endostatin, a fragment of collagen XVIII, is a potent anti-angiogenic protein, but the molecular mechanism of its action is not yet clear. We examined the effects of endostatin on the biological and biochemical activities of vascular endothelial growth factor (VEGF). Endostatin blocked VEGF-induced tyrosine phosphorylation of KDR/Flk-1 and activation of ERK, p38 MAPK, and p125(FAK) in human umbilical vein endothelial cells. Endostatin also inhibited the binding of VEGF(165) to both endothelial cells and purified extracellular domain of KDR/Flk-1. Moreover, the binding of VEGF(121) to KDR/Flk-1 and VEGF(121)-stimulated ERK activation were blocked by endostatin. The direct interaction between endostatin and KDR/Flk-1 was confirmed by affinity chromatography. However, endostatin did not bind to VEGF. Our findings suggest that a direct interaction of endostatin with KDR/Flk-1 may be involved in the inhibitory function of endostatin toward VEGF actions and responsible for its potent anti-angiogenic and anti-tumor activities in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029087     DOI: 10.1074/jbc.M202771200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  127 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

2.  Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells.

Authors:  Chiara M Mazzanti; Anita Tandle; Dominique Lorang; Nick Costouros; David Roberts; Generoso Bevilacqua; Steven K Libutti
Journal:  Genome Res       Date:  2004-08       Impact factor: 9.043

3.  A peptide derived from endostatin ameliorates organ fibrosis.

Authors:  Yukie Yamaguchi; Takahisa Takihara; Roger A Chambers; Kristen L Veraldi; Adriana T Larregina; Carol A Feghali-Bostwick
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

4.  Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin.

Authors:  Akulapalli Sudhakar; Pia Nyberg; Venkateshwar G Keshamouni; Arjuna P Mannam; Jian Li; Hikaru Sugimoto; Dominic Cosgrove; Raghu Kalluri
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

5.  Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery.

Authors:  H M C Shantha Kumara; Samer T Tohme; Xiaohong Yan; Abu Nasar; Anthony J Senagore; Matthew F Kalady; Neil Hyman; Ik Y Kim; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-22       Impact factor: 4.584

6.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

7.  Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.

Authors:  Neel R Sodha; Richard T Clements; Munir Boodhwani; Shu-Hua Xu; Roger J Laham; Cesario Bianchi; Frank W Sellke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

8.  Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.

Authors:  José Augusto Rinck-Junior; Cristiane Oliveira; Gustavo Jacob Lourenço; Regina Aparecida Martinho Sagarra; Sophie Françoise Mauricette Derchain; José Getulio Segalla; Carmen Silvia Passos Lima
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-05       Impact factor: 4.553

9.  Circulating angiogenic biomolecules at rest and in response to upper-limb exercise in individuals with spinal cord injury.

Authors:  Angelo V Vasiliadis; Andreas Zafeiridis; Konstantina Dipla; Nikiforos Galanis; Dimitrios Chatzidimitriou; Antonios Kyparos; Michalis G Nikolaidis; Ioannis S Vrabas
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

10.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.